Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/21827
Title: Estimating costs of care for meningitis infections in low- and middle-income countries
Authors: Portnoy, Allison
Jit, Mark
Lauer, Jeremy
BLOMMAERT, Adriaan 
Ozawa, Sachiko
Stack, Meghan
Murray, Jillian
Hutubessy, Raymond
Issue Date: 2015
Publisher: ELSEVIER SCI LTD
Source: VACCINE, 335, p. A240-A247
Abstract: Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data. We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries. The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines. (C) 2014 Elsevier Ltd. All rights reserved.
Notes: [Portnoy, Allison; Ozawa, Sachiko; Murray, Jillian] Johns Hopkins Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD USA. [Jit, Mark] Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England. [Jit, Mark] Publ Hlth England, Modelling & Econ Unit, London NW9 5EQ, England. [Lauer, Jeremy; Hutubessy, Raymond] WHO, CH-1211 Geneva 27, Switzerland. [Blornmaert, Adriaan] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, CHERMID, B-2610 Antwerp, Belgium. [Blornmaert, Adriaan] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BIOST, BE-3590 Diepenbeek, Belgium.
Keywords: Costs; Meningitis; Hospital; Resource-limited settings;costs; meningitis; hospital; resource-limited settings
Document URI: http://hdl.handle.net/1942/21827
ISSN: 0264-410X
e-ISSN: 1873-2518
DOI: 10.1016/j.vaccine.2014.11.061
ISI #: 000355034500036
Rights: © 2014 Elsevier Ltd. All rights reserved.
Category: A1
Type: Journal Contribution
Validations: ecoom 2016
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
1-s2.0-S0264410X14016454-main.pdf
  Restricted Access
Published version1.32 MBAdobe PDFView/Open    Request a copy
Show full item record

SCOPUSTM   
Citations

16
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

23
checked on Apr 30, 2024

Page view(s)

58
checked on Sep 7, 2022

Download(s)

46
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.